Clay Dehn

Clay Dehn
Clay Dehn

Clay Dehn

Vice President of Clinical Pharmacology Services

Clayton Dehn, MS is a clinical research physiologist with domestic and international experience in the pharmaceutical and device development industry with particular expertise in endocrine disorders, especially those related to fertility and metabolic disturbances. Clay is a co-inventor of a process and substance for disturbing the inheritance pattern of ion- channelopathic disorders by selectively disabling genetically undesirable sperm cells, and is the sole author of the first publication cautioning against the risk of SGLT-inhibition inducing ketoacidosis in insulinopenic populations. Additionally, Clay is a consultant to the Foundation for the National Institute of Health (FNIH) for both:

  • Beta Cell Project tasked with identification and validation of markers to predict long-term beta cell function. The project evaluated short-term measures including the Mixed Meal Tolerance Test (MMTT), Glucagon Stimulation Test, and Arginine Stimulation Test (AST) against the standard Frequently Sampled Intravenous Glucose Tolerance Test in a series of clinical studies to predict long-term beta cell response to interventions and identify individuals whose beta cell function may be at risk for rapid deterioration.
  • Non-Invasive Biomarkers of Metabolic Liver Disease (NIMBLE) consortium working toward the goal of identifying and validating non-invasive biomarker(s) that can eventually replace biopsy in the management of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH)



If you or someone you know is affected by depression, upcoming clinical trials may be an option. Learn more today!


Schizophrenia can affect anyone. If you or someone you know is living with schizophrenia, you may qualify for a clinical trial.


If you or someone you know is diagnosed with diabetes, you may qualify for a clinical trial. Learn more about today.